Briefs: Atlas Life Sciences India and Vidhi Specialty Food Ingredients

Atlas Life Sciences (India) has successfully commenced the commercial production of API - Intermediate at its new plant at Chhatral,

Solara Active Pharma Sciences posts consolidated Q2 FY2024 loss at Rs. 17.16 Cr

Solara Active Pharma Sciences has reported total income of Rs. 426.42 crores during the period ended September 30, 2023

Supriya Lifescience reports Q2 FY24 PAT higher 42% at Rs. 23.88 Cr

SN Bioscience announces Phase 1 study results of SN-38 nanoparticle anti-cancer drug

Impressive safety and efficacy for solid cancer patients followed by global clinical study plan

RPG Life Sciences posts Q2 FY24 PAT at Rs. 25.86 Cr

RPG Life Sciences has reported total income of Rs. 155.41 crores during the period ended September 30, 2023

KKR to invest in life sciences firm Catalio Capital Management

Investment is additive to KKR’s existing health care growth strategy

Ichnos Sciences inks agreement with Astria Therapeutics for OX40 antagonist monoclonal antibody portfolio

Astria will assume full cost and responsibility for the global development and commercialization of the licensed therapeutic program for all indications

Astellas, BioLabs and Mitsui Fudosan collaborate to enhance life science ecosystems in Tsukuba and Kashiwa-no-ha, Japan

Astellas stands on the forefront of healthcare change to turn innovative science into value for patients

Glenmark Pharma to sell 75% stake in Glenmark Life Sciences to Nirma for Rs. 5,652 Cr

Will continue to own a 7.84 per cent stake in Glenmark Life Sciences with the stake reduction

Gufic Biosciences receives TGA Australia and ANVISA Brazil approval for Parecoxib 40mg injection

Parecoxib Sodium is the first parenteral selective COX-2 inhibitor available for clinical use in pain management